Q3 EPS Forecast for Capricor Therapeutics Reduced by Analyst

Key Points

• Capricor Therapeutics experienced a downgrade in Q3 2025 EPS estimates from HC Wainwright, which now predicts a loss of ($0.57) per share, down from a previous estimate of ($0.52).
• Currently, Capricor Therapeutics holds a "Buy" rating with a target price of $24.00, while the consensus target price across analysts is approximately $22.56.
• The company reported a significant earnings miss for the most recent quarter, with an EPS of ($0.57), compared to the consensus estimate of ($0.48).

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) - Investment analysts at HC Wainwright decreased their Q3 2025 earnings per share estimates for shares of Capricor Therapeutics in a report released on Tuesday, August 12th. HC Wainwright analyst J. Pantginis now forecasts that the biotechnology company will post earnings of ($0.57) per share for the quarter, down from their previous estimate of ($0.52). HC Wainwright currently has a "Buy" rating and a $24.00 price target on the stock. The consensus estimate for Capricor Therapeutics' current full-year earnings is ($1.21) per share. HC Wainwright also issued estimates for Capricor Therapeutics' Q4 2025 earnings at ($0.56) EPS, FY2025 earnings at ($2.23) EPS and FY2026 earnings at ($0.88) EPS.

CAPR has been the subject of several other research reports. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $30.00 price target on shares of Capricor Therapeutics in a report on Wednesday, May 14th. Alliance Global Partners reaffirmed a "buy" rating on shares of Capricor Therapeutics in a report on Monday, July 14th. Roth Capital cut their price target on Capricor Therapeutics from $31.00 to $12.00 and set a "buy" rating for the company in a report on Monday, July 14th. Jones Trading cut their price target on Capricor Therapeutics from $40.00 to $29.00 and set a "buy" rating for the company in a report on Wednesday, June 25th. Finally, Piper Sandler reaffirmed an "overweight" rating and issued a $20.00 price target on shares of Capricor Therapeutics in a report on Friday, July 11th. One investment analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $22.56.

Capricor Therapeutics Stock Up 0.1%

Shares of CAPR stock traded up $0.01 during trading hours on Thursday, reaching $7.71. 557,405 shares of the company's stock were exchanged, compared to its average volume of 2,011,235. Capricor Therapeutics has a fifty-two week low of $3.94 and a fifty-two week high of $23.40. The stock has a market capitalization of $352.48 million, a P/E ratio of -4.70 and a beta of 0.59. The business has a fifty day moving average price of $9.06 and a 200-day moving average price of $10.88.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.09). Capricor Therapeutics had a negative return on equity of 62.71% and a negative net margin of 181.71%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Farallon Capital Management LLC acquired a new position in shares of Capricor Therapeutics in the 4th quarter worth approximately $31,056,000. Geode Capital Management LLC raised its position in Capricor Therapeutics by 6.8% in the 2nd quarter. Geode Capital Management LLC now owns 963,080 shares of the biotechnology company's stock worth $9,565,000 after purchasing an additional 61,701 shares during the last quarter. Woodline Partners LP raised its position in Capricor Therapeutics by 15.8% in the 1st quarter. Woodline Partners LP now owns 729,318 shares of the biotechnology company's stock worth $6,921,000 after purchasing an additional 99,384 shares during the last quarter. Altium Capital Management LLC raised its position in Capricor Therapeutics by 150.5% in the 4th quarter. Altium Capital Management LLC now owns 714,000 shares of the biotechnology company's stock worth $9,853,000 after purchasing an additional 429,000 shares during the last quarter. Finally, Octagon Capital Advisors LP bought a new position in Capricor Therapeutics in the 1st quarter worth approximately $4,270,000. 21.68% of the stock is owned by institutional investors and hedge funds.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.